ArticleFrontiers in public health2025
From policy to practice: premarital spinal muscular atrophy screening as a public health initiative in northern Türkiye.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular Atrophy.Annals of neurology · 2026Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal muscular atrophy (SMA) is a severe autosomal recessive neuromuscular disease and a major cause of infant mortality. Türkiye implemented a nationwide premarital SMA carrier screening program in 2021 to reduce disease incidence through early detection and genetic counseling. Methods: This study evaluates the application of the program in a northern province of Türkiye, covering 19,988 individuals screened between December 27, 2021, and May 31, 2024. Results: The carrier prevalence was 2.26% (1:44), and the screening uptake rate was 87.9%. Of 441 screened partners of identified carriers, 13 were also found to be carriers. Seven couples were confirmed as dual carriers and were referred for preimplantation genetic diagnosis (PGD), effectively preventing the birth of affected children. Conclusion: The findings demonstrate the value of premarital screening in populations with high consanguinity rates. The study supports the integration of accessible, socially informed screening practices and highlights the need for further data collection, expanded carrier panels, and enhanced public awareness in Türkiye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.